Surgical management and clinical outcomes of cerebellar liponeurocytomas—a report of seven cases and a pooled analysis of individual patient data

Background: Peginterferon beta-1a and glatiramer acetate (GA) are approved first-line therapies for the treatment of relapsing forms of multiple sclerosis, but their therapeutic efficacy has not been compared directly. Methods: Clinical outcomes at 2 years, including no evidence of disease activity (NEDA), for patients receiving peginterferon beta-1a 125 mcg every 2 weeks (Q2W) or GA 20 mg/ml once daily (QD) were compared by propensity score matching analysis using individual patient data from ADVANCE and CONFIRM phase III clinical trials. In addition, clinical outcomes at 1–3 years for patients receiving peginterferon beta-1a Q2W or GA 40 mg/ml three times a week (TIW) were evaluated using a matching-adjusted comparison analysis of individual patient data from ADVANCE and the ADVANCE extension study, ATTAIN, and aggregate patient data from the phase III GALA and the GALA extension studies. Results: Propensity-score-matched peginterferon beta-1a patients ( n = 336) had a significantly lower annualized relapse rate [ARR (0.204 versus 0.282); rate ratio = 0.724; p = 0.045], a significantly lower probability of 12-week confirmed disability worsening (10.0% versus 14.6%; hazard ratio = 0.625; p = 0.048), and a significantly higher rate of NEDA (20.3% versus 11.5%; p = 0.047) compared with GA 20 mg/ml QD patients after 2 years of treatment. Matching-adjusted peginterferon beta-1a patients (effective n = 276) demonstrated a similar ARR at 1 year (0.278 versus 0.318; p = 0.375) and significantly lower ARR at 2 years (0.0901 versus 0.203; p = 0.032) and 3 years (0.109 versus 0.209; p = 0.047) compared with GA 40 mg/ml TIW patients ( n = 834). Conclusion: Results from separate matching comparisons of phase III clinical trials and extension studies suggest that peginterferon beta-1a 125 mcg Q2W may provide better clinical outcomes than GA (20 mg/ml QD or 40 mg/ml TIW).

Download Full-text

Treatment of renal angiomyolipoma: pooled analysis of individual patient data

BMC Urology ◽

10.1186/s12894-015-0118-2 ◽

2015 ◽

Vol 15 (1) ◽

Cited By ~ 34

Author(s):

Teele Kuusk ◽

Fausto Biancari ◽

Brian Lane ◽

Conrad Tobert ◽

Steven Campbell ◽

...

Keyword(s):

Individual Patient Data ◽

Pooled Analysis ◽

Patient Data ◽

Renal Angiomyolipoma

Download Full-text

Development of imaging-based risk scores for prediction of intracranial haemorrhage and ischaemic stroke in patients taking antithrombotic therapy after ischaemic stroke or transient ischaemic attack: a pooled analysis of individual patient data from cohort studies

The Lancet Neurology ◽

10.1016/s1474-4422(21)00024-7 ◽

2021 ◽

Vol 20 (4) ◽

pp. 294-303

Author(s):

Jonathan G Best ◽

Gareth Ambler ◽

Duncan Wilson ◽

Keon-Joo Lee ◽

Jae-Sung Lim ◽

...

Keyword(s):

Cohort Studies ◽

Ischaemic Stroke ◽

Transient Ischaemic Attack ◽

Antithrombotic Therapy ◽

Intracranial Haemorrhage ◽

Individual Patient Data ◽

Pooled Analysis ◽

Patient Data ◽

Risk Scores ◽

Ischaemic Attack

Download Full-text

2926Long term outcomes of first and second generation drug-eluting stents in patients with diabetes: a pooled analysis of individual patient data from SORT OUT III, IV and V trials

European Heart Journal ◽

10.1093/eurheartj/ehx504.2926 ◽

2017 ◽

Vol 38 (suppl_1) ◽

Author(s):

L.O. Jensen ◽

M. Maeng ◽

J. Ravkilde ◽

C.J. Terkelsen ◽

H.S. Hansen ◽

...

Keyword(s):

Second Generation ◽

Individual Patient Data ◽

Pooled Analysis ◽

Patient Data ◽

Drug Eluting Stents ◽

Patients With Diabetes ◽

Drug Eluting ◽

First And Second Generation

Download Full-text

Association of RASSF1A, DCR2, and CASP8 Methylation with Survival in Neuroblastoma: A Pooled Analysis Using Reconstructed Individual Patient Data

BioMed Research International ◽

10.1155/2020/7390473 ◽

2020 ◽

Vol 2020 ◽

pp. 1-12

Author(s):

Waleed M. Hassan ◽

Mohamed S. Bakry ◽

Timo Siepmann ◽

Ben Illigens

Keyword(s):

Overall Survival ◽

Individual Patient Data ◽

Wide Spectrum ◽

Pooled Analysis ◽

Patient Data ◽

Epigenetic Alterations ◽

Full Data ◽

Data Set ◽

Kaplan Meier ◽

Registration Number

Neuroblastoma (NB) is a heterogeneous tumor affecting children. It shows a wide spectrum of clinical outcomes; therefore, development of risk stratification is critical to provide optimum treatment. Since epigenetic alterations such as DNA methylation have emerged as an important feature of both development and progression in NB, in this study, we aimed to quantify the effect of methylation of three distinct genes (RASSF1A, DCR2, and CASP8) on overall survival in NB patients. We performed a systematic review using PubMed, Embase, and Cochrane libraries. Individual patient data was retrieved from extracted Kaplan–Meier curves. Data from studies was then merged, and analysis was done on the full data set. Seven studies met the inclusion criteria. Methylation of the three genes had worse overall survival than the unmethylated arms. Five-year survival for the methylated arm of RASSF1A, DCR2, and CASP8 was 63.19% (95% CI 56.55-70.60), 57.78% (95% CI 47.63-70.08), and 56.39% (95% CI 49.53-64.19), respectively, while for the unmethylated arm, it was 93.10% (95% CI 87.40–99.1), 84.84% (95% CI 80.04-89.92), and 83.68% (95% CI 80.28-87.22), respectively. In conclusion, our results indicate that in NB patients, RASSF1A, DCR2, and CASP8 methylation is associated with poor prognosis. Large prospective studies will be necessary to confirm definitive correlation between methylation of these genes and survival taking into account all other known risk factors. (PROSPERO registration number CRD42017082264).

Download Full-text